The FRESH study is a randomized, double-blind, placebo-controlled pivotal phase III study, which will be conducted in approximately 70 hospitals worldwide and enroll 502 patients with difficult-to-treat or resistant hypertension. Read the press release
Firibastat could be used in hypertensive and heart failure patients with concomitant renal dysfunction, subject to dose adjustment. Read the press release
Together with their partners, Quantum Genomics is taking all necessary measures to maintain its clinical development activities while ensuring that the safety of its staff and enrolled patients remains its top priority. Read the press release
Given the current public health crisis, and in order to prepare for its financial consequences, Quantum Genomics has secured new financing thanks to an agreement with Negma Group Ltd, dated March 26, 2020. Read the press release